Oak Ridge Investments LLC Sells 3,736 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Oak Ridge Investments LLC lowered its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 2.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 123,806 shares of the company’s stock after selling 3,736 shares during the period. Oak Ridge Investments LLC owned approximately 0.06% of Hims & Hers Health worth $2,281,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its position in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC raised its position in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares in the last quarter. CWM LLC raised its position in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at approximately $111,000. Finally, Amalgamated Bank raised its position in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $18.85 on Friday. The firm’s fifty day moving average is $17.94 and its 200-day moving average is $18.01. Hims & Hers Health, Inc. has a 52 week low of $5.76 and a 52 week high of $25.74. The firm has a market cap of $4.05 billion, a P/E ratio of 235.59 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.03) earnings per share. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hims & Hers Health news, COO Melissa Baird sold 16,784 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $17.00, for a total transaction of $285,328.00. Following the transaction, the chief operating officer now owns 585,800 shares in the company, valued at approximately $9,958,600. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 858,665 shares of company stock valued at $15,148,890 over the last ninety days. 17.71% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

HIMS has been the subject of several analyst reports. Bank of America boosted their target price on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Piper Sandler reiterated a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Finally, Truist Financial upped their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and an average price target of $20.21.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.